ReviewDiagnostics (Basel, Switzerland)2026
Machine Learning Applications for Risk Stratification in Heart Failure with Preserved Ejection Fraction: A New Era in Cardiology.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel blood biomarkers for heart failure mortality: mechanistic pathways, aging biology, and risk stratification.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and heterogeneous syndrome with limited therapeutic options, making accurate risk stratification essential yet challenging. Traditional tools such as the H2FPEF and HFA-PEFF scores incorporate few variables and demonstrate modest prognostic performance. Machine learning (ML) offers enhanced risk prediction by integrating multidimensional clinical, imaging, biomarker, and molecular data. This review summarizes current ML applications in HFpEF, including random forests, gradient boosting, support vector machines, and deep learning, highlighting their superior discrimination and ability to reveal phenotypic subgroups with distinct outcomes. We also address practical considerations such as interpretability, real-world validation, and integration into clinical workflows, as well as challenges related to data bias, generalizability, and regulatory requirements. Future opportunities include real-time clinical decision support, digital health integration, and interventional ML to guide personalized therapy. ML holds significant potential to advance precision care and improve outcomes in HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.